argenx NV ADR (ARGX)vsGinkgo Bioworks Holdings (DNA)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
DNA
Ginkgo Bioworks Holdings
$7.36
+2.65%
HEALTHCARE · Cap: $415.51M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 2390% more annual revenue ($4.24B vs $170.16M). ARGX leads profitability with a 30.5% profit margin vs -1.8%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
DNA
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for DNA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -51.1% — below average capital efficiency
Revenue declined 23.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while DNA is a turnaround play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.59 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 33/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a pioneering leader in the synthetic biology sector, utilizing advanced genetic engineering technologies to create customized bioengineered organisms for applications in pharmaceuticals, agriculture, and industrial biotech. Its proprietary platform significantly enhances cellular design for manufacturing, streamlining product development and production processes. Dedicated to addressing global challenges such as climate change and food security, Ginkgo is strategically positioned to influence a wide array of industries while driving sustainable innovation. With its commitment to bio-based solutions, the company is poised for robust growth in a rapidly evolving biotech landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?